Terlipressin, a new drug, has been registered
Mir-Pharm announces successful registration of new orphan drug
Moscow, October 2023
The drug contains the active substance terlipressin.
Terlipressin is a synthetic analogue of vasopressin (hormone of the posterior lobe of the pituitary gland), it has a pronounced vasoconstrictive and styptic effect.
Terlipressin causes contraction of arterioles, veins and venules of visceral organs, which results in decreased blood flow through the liver and reduced pressure in the portal system.
Terlipressin stimulates contraction of esophageal smooth muscle, increases tone and enhances intestinal peristalsis.
Terlipressin, acting on uterine smooth muscle, increases contractile activity of myometrium (regardless of the presence of pregnancy).
Note:
The press release contains information about prescription medications. Use of this information for preparation of publications must be made in accordance with the legislation of the Russian Federation on advertising (including but not limited to Art. 24 of the Federal Law of 13.03.2006 No. 38-FL "On Advertising"), according to which, in particular, advertising of prescription drugs is allowed only in places of medical or pharmaceutical exhibitions, workshops, conferences and other similar events as well as in specialized print media intended for medical and pharmaceutical workers. Failure to comply with the above requirements (namely, mentioning the name of the drug, placing an image of the package or its elements in the media other than specialized print publications intended for medical and pharmaceutical workers) shall entail administrative liability.